All In Biotech

Drug Trial Radar · NCT00621959

A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine 5 mg Once Daily Given for 2 Weeks in Subjects 18 yr of Age and Older With Seasonal Allergic Rhinitis

Last checked: Nov 20, 2026Latest source record: Jul 16, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 596 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

596

Actual

Start

Mar 2008

Primary completion

Jun 2008

Study completion Jun 2008

Sponsor

Lead sponsor
UCB PharmaUCB
Sponsor type
Industry
First posted
Feb 22, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study objective is to investigate the efficacy of levocetirizine in reducing symptoms associated with seasonal allergic rhinitis and in improving rhinitis-related Quality of Life

Conditions

  • Seasonal Allergic Rhinitis

Interventions

  • levocetirizine dihydrochlorideDrug

    5mg daily (oral tablet) for 14 days

  • placeboDrug

    0mg (matching oral tablet)for 14 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean 24-hour Reflective Total 5 Symptoms Score (T5SS)Time frame: Over the total treatment period (14 days)

Locations

26 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Hot Springs, Arkansas

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Huntington Beach, California

  • Site not named

    Long Beach, California

  • Site not named

    Los Angeles, California

  • Site not named

    Mission Viejo, California

  • Site not named

    Albany, Georgia

  • Site not named

    Lilburn, Georgia

  • Site not named

    Savannah, Georgia

  • Site not named

    Owensboro, Kentucky

  • Site not named

    Metairie, Louisiana

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Tulsa, Oklahoma

  • Site not named

    Charleston, South Carolina

  • Site not named

    Knoxville, Tennessee

  • Site not named

    Austin, Texas

  • Site not named

    Dallas, Texas

  • Site not named

    El Paso, Texas

  • Site not named

    Fort Worth, Texas

  • Site not named

    Katy, Texas

  • Site not named

    New Braunfels, Texas

  • Site not named

    Plano, Texas

  • Site not named

    San Angelo, Texas

  • Site not named

    San Antonio, Texas

  • Site not named

    Waco, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.